Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Ilaprazole for GERD: A Randomized, Double-Blind, Esomeprazole-Controlled, Phase 3, Multicenter Trial in China

NCT02860624 is registered in ClinicalTrials.gov with Livzon Pharmaceutical Group Inc. as lead sponsor.

NCT NCT02860624
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02860624 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Ilaprazole for GERD: A Randomized, Double-Blind, Esomeprazole-Controlled, Phase 3, Multicenter Trial in China
Lead sponsor
Livzon Pharmaceutical Group Inc.
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2011
Completion date
Not reported
Enrollment
550 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gastroesophageal reflux disease